MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine TherapyGeorge W. Sledge, Antonio Llombart‐Cussac, Olga Burdaeva et al.|Journal of Clinical Oncology|2017Cited by 1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2George W. Sledge, Antonio Llombart‐Cussac, Masakazu Toi et al.|JAMA Oncology|2019Cited by 983
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancerDaniel Morgensztern, Pilar Garrido, Nina Karaseva et al.|Lung Cancer|2019Cited by 24